Integration of antimicrobial peptides and gold nanorods for bimodal antibacterial applications

2020 ◽  
Vol 8 (16) ◽  
pp. 4447-4457
Author(s):  
Jin Chen ◽  
Tingting Dai ◽  
Jiawei Yu ◽  
Xiahong Dai ◽  
Richai Chen ◽  
...  
Keyword(s):  
Antimicrobial Peptides ◽  
Antimicrobial Peptide ◽  
Gold Nanorods ◽  
Bacterial Activity ◽  
Resistant Bacteria ◽  
Drug Resistant ◽  
Drug Resistant Bacteria

We integrate the anti-bacterial activity of BF2b antimicrobial peptide and the photothermal sterilization of gold nanorods to kill drug-resistant bacteria.

scholarly journals Nanoparticles Enable Efficient Delivery of Antimicrobial Peptides for the Treatment of Deep Infections

2021 ◽  
Author(s):  
Yingxue Deng ◽  
Rui Huang ◽  
Songyin Huang ◽  
Menghua Xiong
Keyword(s):  
Antimicrobial Peptides ◽  
Broad Spectrum ◽  
Antimicrobial Properties ◽  
Therapeutic Index ◽  
Resistant Bacteria ◽  
Drug Resistant ◽  
Drug Resistant Bacteria ◽  
Efficient Delivery ◽  
Delivery Vehicles

Antimicrobial peptides (AMPs) have emerged as promising alternatives of traditional antibiotics against drug-resistant bacteria owing to their broad-spectrum antimicrobial properties and low tendency to drugresistance. However, their therapeutic efficacy in vivo, especially for infections in deep organs, is limited owing to their systemic toxicity and low bioavailability. Nanoparticles-based delivery systems offer a strategy to increase the therapeutic index of AMPs by preventing proteolysis, increasing the accumulation at infection sites, and reducing toxicity. Herein, we will discuss the current progress of using nanoparticles as delivery vehicles for AMPs for the treatment of deep infections.

scholarly journals Design, Engineering and Discovery of Novel α-Helical and β-Boomerang Antimicrobial Peptides against Drug Resistant Bacteria

2020 ◽  
Vol 21 (16) ◽  
pp. 5773 ◽  
Author(s):  
Surajit Bhattacharjya ◽  
Suzana K. Straus
Keyword(s):  
Antimicrobial Peptides ◽  
Resistant Bacteria ◽  
Drug Resistant ◽  
Antibiotic Development ◽  
Extensively Drug Resistant ◽  
Drug Resistant Bacteria ◽  
Drying Up ◽  
Further Development ◽  
Lps Binding

In an era where the pipeline of new antibiotic development is drying up, the continuous rise of multi-drug resistant (MDR) and extensively drug resistant (XDR) bacteria are genuine threats to human health. Although antimicrobial peptides (AMPs) may serve as promising leads against drug resistant bacteria, only a few AMPs are in advanced clinical trials. The limitations of AMPs, namely their low in vivo activity, toxicity, and poor bioavailability, need to be addressed. Here, we review engineering of frog derived short α-helical AMPs (aurein, temporins) and lipopolysaccharide (LPS) binding designed β-boomerang AMPs for further development. The discovery of novel cell selective AMPs from the human proprotein convertase furin is also discussed.

Antimicrobial peptide HPA3NT3-A2 effectively inhibits biofilm formation in mice infected with drug-resistant bacteria

2019 ◽  
Vol 7 (12) ◽  
pp. 5068-5083 ◽  
Author(s):  
Jong-Kook Lee ◽  
Loredana Mereuta ◽  
Tudor Luchian ◽  
Yoonkyung Park
Keyword(s):  
Antibiotic Resistance ◽  
Antimicrobial Peptide ◽  
Biofilm Formation ◽  
Extracellular Polymeric Substances ◽  
Resistant Bacteria ◽  
Bacterial Biofilms ◽  
Drug Resistant ◽  
Drug Resistant Bacteria ◽  
Serious Infections

Bacterial biofilms formed through secretion of extracellular polymeric substances (EPS) have been implicated in many serious infections and can increase antibiotic resistance by a factor of more than 1000.

scholarly journals LAMP2: a major update of the database linking antimicrobial peptides

Database ◽  
2020 ◽  
Vol 2020 ◽  
Author(s):  
Guizi Ye ◽  
Hongyu Wu ◽  
Jinjiang Huang ◽  
Wei Wang ◽  
Kuikui Ge ◽  
...  
Keyword(s):  
Antimicrobial Peptides ◽  
Primary Structure ◽  
Scientific Community ◽  
Resistant Bacteria ◽  
Drug Resistant ◽  
Current Version ◽  
Functional Activities ◽  
Drug Resistant Bacteria ◽  
Functional Classes ◽  
And Function

Abstract Antimicrobial peptides (AMPs) have been regarded as a potential weapon to fight against drug-resistant bacteria, which is threating the globe. Thus, more and more AMPs had been designed or identified. There is a need to integrate them into a platform for researchers to facilitate investigation and analyze existing AMPs. The AMP database has become an important tool for the discovery and transformation of AMPs as agents. A database linking antimicrobial peptides (LAMPs), launched in 2013, serves as a comprehensive tool to supply exhaustive information of AMP on a single platform. LAMP2, an updated version of LAMP, holds 23 253 unique AMP sequences and expands to link 16 public AMP databases. In the current version, there are more than 50% (12 236) sequences only linking a single database and more than 45% of AMPs linking two or more database links. Additionally, updated categories based on primary structure, collection, composition, source and function have been integrated into LAMP2. Peptides in LAMP2 have been integrated in 8 major functional classes and 38 functional activities. More than 89% (20 909) of the peptides are experimentally validated peptides. A total of 1924 references were extracted and regarded as the evidence for supporting AMP activity and cytotoxicity. The updated version will be helpful to the scientific community.

scholarly journals All d-Lysine Analogues of the Antimicrobial Peptide HPA3NT3-A2 Increased Serum Stability and without Drug Resistance

2020 ◽  
Vol 21 (16) ◽  
pp. 5632
Author(s):  
Jong-Kook Lee ◽  
Yoonkyung Park
Keyword(s):  
Staphylococcus Aureus ◽  
Antimicrobial Activity ◽  
Antimicrobial Peptide ◽  
Proteolytic Enzymes ◽  
Resistant Bacteria ◽  
Drug Resistant ◽  
Peptide Bonds ◽  
Drug Resistant Bacteria ◽  
Antibiotic Drugs ◽  
Strong Antimicrobial Activity

Novel antibiotic drugs are urgently needed because of the increase in drug-resistant bacteria. The use of antimicrobial peptides has been suggested to replace antibiotics as they have strong antimicrobial activity and can be extracted from living organisms such as insects, marine organisms, and mammals. HPA3NT3-A2 ([Ala1,8] HPA3NT3) is an antimicrobial peptide that is an analogue of the HP (2–20) peptide derived from Helicobacter pylori ribosomal protein L1. Although this peptide was shown to have strong antimicrobial activity against drug-resistant bacteria, it also showed lower toxicity against sheep red blood cells (RBCs) and HaCaT cells compared to HPA3NT3. The l-Lys residues of HPA3NT3-A2 was substituted with d-Lys residues (HPA3NT3-A2D; [d-Lys2,5,6,9,10,15] HPA3NT3-A2) to prevent the cleavage of peptide bonds by proteolytic enzymes under physiological conditions. This peptide showed an increased half-life and maintained its antimicrobial activity in the serum against Escherichia coli (E. coli) and Staphylococcus aureus (S. aureus) (pathogen). Furthermore, the antimicrobial activity of HPA3NT3-A2D was not significantly affected in the presence of mono- or divalent ions (Na+, Mg2+, Ca2+). Finally, l- or d-HPA3NT3-A2 peptides exhibited the strongest antimicrobial activity against antibiotic-resistant bacteria and failed to induce resistance in Staphylococcus aureus after 12 passages.

scholarly journals Mass Balance Study of the Engineered Cationic Antimicrobial Peptide, WLBU2, Following a Single Intravenous Dose of 14C-WLBU2 in Mice.

2020 ◽  
Vol 15 ◽  
Author(s):  
Jan H. Beumera ◽  
Jianxia Guo ◽  
Evan C. Ray ◽  
Jonas Scemama ◽  
Robert A. Parise ◽  
...  
Keyword(s):  
Multidrug Resistance ◽  
Antimicrobial Peptides ◽  
Mass Balance ◽  
Bacterial Infections ◽  
Resistant Bacteria ◽  
Drug Resistant ◽  
Balance Study ◽  
Drug Resistant Bacteria ◽  
Mouse Tissues ◽  
Mass Balance Study

Background: To address multidrug resistance we developed engineered cationic antimicrobial peptides (eCAPs). Lead eCAP WLBU2 displays potent activity against drug-resistant bacteria and effectively treats lethal bacterial infections in mice reducing bacterial loads to undetectable levels in diverse organs. Background: To address multidrug resistance we developed engineered cationic antimicrobial peptides (eCAPs). Lead eCAP WLBU2 displays potent activity against drug-resistant bacteria and effectively treats lethal bacterial infections in mice reducing bacterial loads to undetectable levels in diverse organs. Objective: To support development of WLBU2, we conducted a mass balance study. Methods: CD1 mice were administered 10, 15, 20 and 30 mg/kg QDx5 WLBU2 or a single dose of [14C]-WLBU2 at 15 mg/kg IV. Tolerability, tissue distribution and excretion were evaluated with liquid scintillation and HPLCradiochromatography. Results: The maximum tolerated dose of WLBU2 is 20 mg/kg IV. We could account for greater than >96% of the radioactivity distributed within mouse tissues at 5 and 15 min. By 24 h, only ~40-50% of radioactivity remained in the mice. The greatest % of the dose was present in liver, accounting for ~35% of radioactivity at 5 and 15 min, and ~ 8% of radioactivity remained at 24 h. High radioactivity was also present in kidneys, plasma, red blood cells and lungs, while less than 0.2% of radioactivity was present in brain, fat, or skeletal muscle. Urinary and fecal excretion accounted for 12.5 and 2.2% of radioactivity at 24 h. Conclusion: WLBU2 distributes widely to mouse tissues and is rapidly cleared with a terminal radioactivity half-life of 22 h, a clearance of 27.4 mL/h/kg, and a distribution volume of 0.94 L/kg. At 2-100 µg-eq/g, the concentrations of 14CWLBU2 appear high enough in the tissues to account for inhibition of microbial growth.

scholarly journals Isolation and Identification of Multi-drug Resistant Bacteria from various sources and Antimicrobial Activity of Terminalia chebula Retz against isolated Multi-drug Resistant Bacteria

2021 ◽  
Vol 11 (4) ◽  
pp. 7338-7344
Author(s):  
Tamalika Chakraborty ◽  
Kanchan Chettri ◽  
Sumana Chatterjee ◽  
Lopamudra Datta ◽  
Abhijit Sengupta
Keyword(s):  
Drug Resistance ◽  
Minimum Inhibitory Concentration ◽  
Inhibitory Concentration ◽  
Minimum Bactericidal Concentration ◽  
Bacterial Activity ◽  
Resistant Bacteria ◽  
Drug Resistant ◽  
Terminalia Chebula ◽  
Isolation And Identification ◽  
Drug Resistant Bacteria

Drug resistance is a threat to civilization, which results from over-prescription and irrational use of antibiotics. This has led to an increased demand for novel leads of herbal origin to overcome drug resistance. The present work involves the screening of various antibiotics against isolated Staphylococcus sp. from Hospital Effluent and the Minimum Inhibitory concentration for antibiotics namely Vancomycin, Erythromycin and Oxacillin were found to be 7.33+0.6 µg/ml 25.33+0.6 µg/ml and 27.33+0.6 µg/ml respectively whereas Minimum bactericidal concentration of Vancomycin, Erythromycin and oxacillin was found to be 180µg/ml; 146.67 + 0.3 µg/ml and 96.66 + 0.6 µg/ml respectively. Thus, the isolated bacteria were proved to be Multi-Drug Resistant. Haritaki (Terminalia chebula Retz) is given potential importance in Ayurveda for its properties to cure and prevent diseases. Terminalia chebula Retz is often known as “King of Medicines” and enlisted in Ayurveda for its extraordinary therapeutic contribution. The proved Multi-Drug Resistant bacteria was further subjected to a crude extract of Haritaki. Minimum Inhibitory Concentration for Terminalia chebula was found to be 1.33 +0.3 mg/ml and thus proved to be exhibiting potential anti-bacterial activity against isolated Multi-Drug Resistant Staphylococcus sp.

Sign in / Sign up

Export Citation Format

Share Document